HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Low-Carb, Supplement Cross-Promotion, Sustainability Pondered By Retailers

This article was originally published in The Tan Sheet

Executive Summary

The National Nutritional Foods Association and Natural Marketing Institute are encouraging natural product retailers to explore joint promotion of supplements and low-carb offerings, while some industry stakeholders suggest that the popular diet approach may be fading

You may also be interested in...



Slim Fast Forgoes Classic Products In Favor Of Low Carb Diet, Optima Lines

Slim Fast will completely phase out its original product line by the beginning of 2005 and switch to a two-diet approach: the recently launched Slim Fast Low Carb Diet line and the new Slim Fast Optima offerings for optimum nutrition

Low-Carb Health Consequences Create Supplement Opportunity – Consultant

Dietary supplement makers should leverage the low-carb dieting trend by looking at ingredients for GI health and positioning other products that address the health consequences of a low-carb diet, according to Steve French, marketing partner for the Natural Marketing Institute (NMI)

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel